ArticleNutrients2021
Plasma Imidazole Propionate Is Positively Correlated with Blood Pressure in Overweight and Obese Humans.
Article in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 28 citations in OpenAlex.
- Cardiovascular-kidney-metabolic syndrome through the lens of gut‑derived uremic toxins.Gut microbes · 2026Review
- Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology.Nature communications · 2026Article
- Circulating imidazole propionate and coronary heart disease risk: interplay between histidine intake, fiber, and gut microbiome.BMC medicine · 2026Article
- The Role of the Gut Microbiota in Functional Recovery after Peripheral Nerve Injury: A Narrative Review.Orthopedic reviews · 2026Article
- Article
- Article
- Comparative serum imidazole propionate profiling in colorectal adenoma and cancer by UPLC-MS/MS.BMC gastroenterology · 2025Article
- Inflammation mediates the effect of histidine on a lower risk of colorectal cancer.Frontiers in nutrition · 2025Article
- Gut microbiota-derived imidazole propionate: an emerging target for the prevention and treatment of cardiometabolic diseases.Frontiers in endocrinology · 2025Review
- Editorial: Gut microbiota-derived metabolites and cardiovascular diseases.Frontiers in cellular and infection microbiology · 2025Article
- Kinetics of imidazole propionate from orally delivered histidine in mice and humans.NPJ biofilms and microbiomes · 2024Article
- Gut microbiota-generated metabolites: missing puzzles to hosts' health, diseases, and aging.BMB reports · 2024Review
- Relationships and Mendelian Randomization of Gut Microbe-Derived Metabolites with Metabolic Syndrome Traits in the METSIM Cohort.Metabolites · 2024Article
- Imidazole propionate in type 2 diabetes mellitus and cardiovascular diseases: a mini review.Frontiers in immunology · 2024Review
- Article
- Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection.Microbiome · 2023Article
- The Gut Microbiome, Microbial Metabolites, and Cardiovascular Disease in People Living with HIV.Current HIV/AIDS reports · 2023Review
- Metabolite profiles of diabetes mellitus and response to intervention in anti-hyperglycemic drugs.Frontiers in endocrinology · 2023Review
- Metabolomic and Proteomic Identification of Serum Exosome for Hypoxic Preconditioning Participants.Oxidative medicine and cellular longevity · 2023Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundThe gut microbiota and its metabolites are essential for host health and dysbiosis has been involved in several pathologic conditions such as type 2 diabetes (T2D) and cardiovascular disease (CVD). Recent studies have identified that plasma imidazole propionate (ImP), a microbial-produced metabolite, is increased in patients with prediabetes and T2D. More recently, ImP was found to be significantly increased in patients with overt CVD. Here, we aimed to investigate the association between ImP and CVD risk factors: blood pressure, HDL-cholesterol, LDL-cholesterol and insulin-resistance in overweight and obese subjects without T2D or use of any metabolic diseases-related medication.
methodsPlasma metabolites, including ImP, were determined in 107 male or post-menopausal women with overweight/obesity, but without T2D. Insulin-sensitivity was assessed with the gold standard method: the hyperinsulinemic-euglycemic clamp using the isotope [6,6-
resultsPartial correlation analysis controlled for BMI and age showed a significant correlation between ImP and diastolic blood pressure (r
conclusionIn this cohort with overweight/obese subjects without T2D, plasma ImP concentrations were positively correlated with diastolic blood pressure but not with insulin-sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.